PE-22-28: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 9 sources cited
Overview
PE-22-28 is a synthetic peptide derived from the spadin family that acts as a blocker of the TREK-1 potassium channel. TREK-1 inhibition produces rapid antidepressant and cognitive-enhancing effects, making PE-22-28 a novel nootropic with mood-elevating properties. It represents a fundamentally different approach to cognitive enhancement and mood regulation compared to traditional monoamine-targeting compounds.
Mechanism of Action
PE-22-28 is a 7-amino-acid peptide that selectively blocks the TREK-1 (TWIK-related potassium channel-1), a two-pore-domain potassium channel highly expressed in the hippocampus, prefrontal cortex, and amygdala. TREK-1 normally acts as a 'leak' potassium channel that stabilizes resting membrane potential, and blocking it increases neuronal excitability in mood- and cognition-relevant brain regions. This produces effects analogous to SSRIs but through an entirely different mechanism and with a much faster onset. In mice, TREK-1 blockade by spadin raised the firing of serotonin neurons in the dorsal raphe and increased hippocampal neurogenesis and BDNF; for PE-22-28 itself, neurogenesis and synaptogenesis have been measured, but not BDNF. The faster onset in mice, 4 days against 21 for classical antidepressants, is attributed to direct modulation of neuronal excitability rather than slow reuptake transporter adaptations.
PE-22-28 Benefits: What the Research Shows
- Moha Ou Maati et al. (2012) in Neuropharmacology reported that spadin (the parent compound) produced antidepressant effects in mice within 4 days, against 21 days for classical antidepressants
- Research showed TREK-1 knockout mice exhibit a depression-resistant phenotype, validating the target (Nature Neuroscience, 2006)
- Studies demonstrated PE-22-28 increased hippocampal neurogenesis after only four days of treatment in mice and raised PSD-95 in cortical neurons; the BDNF increase was shown for spadin
- Preclinical data showed PE-22-28 reduced immobility in the forced swimming test and shortened the latency to eat in the novelty suppressed feeding test in mice
- Research in Frontiers in Pharmacology found PE-22-28 blocked TREK-1 with an IC50 of 0.12 nM, several hundred times more potently than spadin, and spadin itself did not inhibit the related channels TREK-2, TRAAK, TASK or TRESK
PE-22-28 Dosage
- Intranasal: 50–200 mcg per dose, 1–2 times daily
- Subcutaneous: 100–500 mcg once daily
- Start with 50 mcg intranasally to assess response
- Cycle: 2–4 weeks on, 1–2 weeks off
- Morning dosing preferred for cognitive enhancement; evening dosing may benefit mood and next-day resilience
- Effects may be noticeable within hours due to the fast-onset mechanism
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
PE-22-28 Side Effects & Safety
Known Side Effects
- Headache — reported in some users, generally mild
- Overstimulation — potential for restlessness or anxiety at higher doses, particularly in anxiety-prone individuals
- Insomnia — if dosed too late in the day
- Very limited human safety data — almost all evidence is preclinical
- Nasal irritation with intranasal administration
Safety Profile
PE-22-28 is a research compound with no human clinical trial data. Its safety profile is extrapolated from preclinical studies and the broader spadin literature. TREK-1 is widely expressed in the brain, and modulating its activity could have effects beyond mood and cognition. The compound has not been assessed for genotoxicity, carcinogenicity, or reproductive toxicity. Users should treat it as an experimental compound with appropriate caution. Individuals on SSRIs, SNRIs or other antidepressants should exercise caution: combining spadin with a serotonergic drug in rats paradoxically shut down serotonin neuron firing, which the authors read as depolarisation block.
What to Expect
Within hours: Some users report subtle mood elevation and improved motivation within the first day, though the fast onset shown in preclinical studies was 4 days of treatment in mice, not hours. Days 1–3: Improved mood stability and cognitive clarity. Tasks feel less effortful and motivation increases. Weeks 1–2: Cumulative neurogenic effects emerge. Users report improved emotional resilience, better stress management, and enhanced cognitive flexibility. Weeks 3–4: Peak effects. Mood is notably improved and stable, cognitive performance is enhanced, and overall sense of well-being is elevated. After cessation, effects taper over 1–2 weeks.
Common Stacks
N-Acetyl Semax Amidate
NASA provides BDNF upregulation and dopaminergic enhancement while PE-22-28 adds serotonergic modulation and TREK-1-mediated mood support — comprehensive neurocognitive enhancement
Noopept
Noopept's glutamatergic cognitive enhancement complements PE-22-28's mood-elevating and neurogenic effects
NA-Selank Amidate
Selank provides anxiolytic GABAergic modulation that balances PE-22-28's excitatory effects, creating enhanced cognition without overstimulation
Storage & Handling
Store lyophilized PE-22-28 at -20°C for long-term storage or 2–8°C for up to 3 months. Reconstitute with bacteriostatic water or sterile saline. After reconstitution, refrigerate and use within 3–4 weeks. As a short peptide, it is moderately stable but should be protected from heat and light.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Djillani A, Pietri M, Moreno S, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017.
- Mazella J, Pétrault O, Lucas G, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010.
- Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci. 2006.
- Moha Ou Maati H, Veyssiere J, Labbal F, et al. Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology. 2012.
- Devader C, Khayachi A, Veyssière J, et al. In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin. Br J Pharmacol. 2015.
- Moha ou Maati H, Bourcier-Lucas C, Veyssiere J, et al. The peptidic antidepressant spadin interacts with prefrontal 5-HT(4) and mGluR(2) receptors in the control of serotonergic function. Brain Struct Funct. 2016.
- Djillani A, Mazella J, Heurteaux C, et al. Role of TREK-1 in Health and Disease, Focus on the Central Nervous System. Front Pharmacol. 2019.
- Veyssiere J, Moha Ou Maati H, Mazella J, et al. Retroinverso analogs of spadin display increased antidepressant effects. Psychopharmacology (Berl). 2015.
- Pietri M, Djillani A, Mazella J, et al. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology. 2019.
Related Peptides
Track PE-22-28 in Your Protocol
Log your PE-22-28 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free